RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope

To date, gene therapy with transiently derived lentivectors has been very successful to cure rare infant genetic diseases. However, transient manufacturing is unfeasible to treat adult malignancies because large vector lots are required. By contrast, stable manufacturing is the best option for high-...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mol Ther Methods Clin Dev
Autores principales: Marin, Virna, Stornaiuolo, Anna, Piovan, Claudia, Corna, Stefano, Bossi, Sergio, Pema, Monika, Giuliani, Erica, Scavullo, Cinzia, Zucchelli, Eleonora, Bordignon, Claudio, Rizzardi, Gian Paolo, Bovolenta, Chiara
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4863723/
https://ncbi.nlm.nih.gov/pubmed/27222840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mtm.2016.33
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares